Endocrine Balance
Breast cancer drug Etcamah fails first-line trial test
By emily johnson · 244
Microbiome Diversity
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
By emily johnson · 223
Nutrient Synergy
AbbVie tests new approach for menstrual migraine treatment
By Samoyed · 169
Endocrine Balance
Biotechs lead fight against cancer
By emily johnson · 471 Views · September 11, 2026
Breast cancer drug Etcamah fails first-line trial test
By emily johnson
Biotechs lead fight against cancer
By emily johnson
Microbiome Diversity 
Microbiome Diversity 
Microbiome Diversity 
Microbiome Diversity 
In-Depth Analysis Pharmacy Landscape in Indonesia
0 by Samoyed
Ivonescimab Meets Overall Survival Goal in NSCLC
0 by emily johnson
Recovery Modalities
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
September 4, 2026
Recovery Modalities
HiRO and Differentia Biotech collaborate on trial simulation
HiRO and Differentia Biotech collaborate on advanced clinical trial simulation models. Learn how this AI-driven partnership aims to...
August 31, 2026
Recovery Modalities
Daiichi Sankyo Begins Phase I DS1025 Trial
First patient dosing has begun in the Phase I DS1025 study , a trial that will assess an...
August 29, 2026
Editor's picks
Why Is Medicaid Member Engagement Essential for Health
Medicaid is a cornerstone of healthcare access for millions of Americans, including low-income families, seniors, and individuals with disabilities. While...
August 27, 2026
ESC 2026 AstraZeneca oral relaxin passes Phase II
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
September 2, 2026
ESC 2026 AstraZeneca oral relaxin passes Phase II
By Samoyed · Sep 2, 2026
Why Is Medicaid Member Engagement Essential for Health
By Samoyed · Aug 27, 2026
All Post
Endocrine Balance
Breast cancer drug Etcamah fails first-line trial test
AstraZeneca’s breast cancer drug Etcamah failed its first-line trial, SERENA-4, raising doubts about its potential as a frontline treatment for HR-positive pati
emily johnson 259 Views September 15, 2026
Microbiome Diversity
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
Novo Nordisk drops its full name to become 'Novo,' sharpening focus against Eli Lilly in weight loss and diabetes treatments amid slowing growth.
emily johnson 123 Views September 14, 2026
Nutrient Synergy
AbbVie tests new approach for menstrual migraine treatment
AbbVie’s Qulipta becomes first oral CGRP inhibitor to succeed in phase 3 menstrual migraine trials, offering hope for resistant cases.
Samoyed 124 Views September 12, 2026
Endocrine Balance
Biotechs lead fight against cancer
Biotechs lead the fight against cancer with next-generation treatments and clinical trials.
emily johnson 281 Views September 11, 2026
Recovery Modalities
Bayer Moves Hyrnuo Into Frontline Lung Cancer
Bayer secured FDA approval for Hyrnuo lung cancer treatment, marking a major shift in frontline HER2-mutant NSCLC care based on new clinical data.
Samoyed 281 Views September 10, 2026
Microbiome Diversity
Bristol Myers reports progress in multiple myeloma trial
Bristol Myers reports progress in multiple myeloma trial with arlocabtagene autoleucel showing promise.
Samoyed 110 Views September 9, 2026
Microbiome Diversity
Guidelines for e-signature use in global trials
Guidelines for e-signature use in global trials, including qualified e-signature and standard e-signature options.
emily johnson 151 Views September 8, 2026
Nutrient Synergy
Ivonescimab Meets Overall Survival Goal in NSCLC
Ivonescimab surpasses Keytruda in overall survival for NSCLC first-line treatment, demonstrating potential breakthrough in lung cancer therapy.
emily johnson 246 Views September 7, 2026
Recovery Modalities
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
Samoyed 137 Views September 4, 2026
Nutrient Synergy
Alumis lupus drug advances after trial setback
Alumis advances its lupus drug to Phase III trials despite mixed Phase IIb results, targeting a specific patient subgroup for better outcomes.
Samoyed 171 Views September 3, 2026